Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Denali Capital Acquisition Corp. Class A Ordinary Shares (DECA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/11/2025: DECA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 8.13% | Avg. Invested days 109 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.00M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.33 | 52 Weeks Range 10.52 - 13.20 | Updated Date 06/29/2025 |
52 Weeks Range 10.52 - 13.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.45% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33107381 | Price to Sales(TTM) - |
Enterprise Value 33107381 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 32.75 | Shares Outstanding 1261840 | Shares Floating 763035 |
Shares Outstanding 1261840 | Shares Floating 763035 | ||
Percent Insiders 40.42 | Percent Institutions 55.96 |
Upturn AI SWOT
Denali Capital Acquisition Corp. Class A Ordinary Shares
Company Overview
History and Background
Denali Capital Acquisition Corp. was a blank check company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It did not have any specific business combination under consideration. It appears to have completed a business combination with Akili, Inc. and subsequently changed its name.
Core Business Areas
- Blank Check Company (formerly): Prior to its business combination, it was a special purpose acquisition company (SPAC) with no operating history or revenues.
Leadership and Structure
As a SPAC, Denali Capital Acquisition Corp. had a management team focused on identifying and acquiring a target company. Details beyond that require knowing the specific leadership and structure of Denali post-merger with Akili.
Top Products and Market Share
Key Offerings
- Akili Interactive Labs: Akili Interactive Labs, focused on cognitive treatments through video games, is the offering now. They develop digital therapeutics targeted at cognitive impairments. Competitors include other digital therapeutics companies and more traditional pharmaceutical companies in the cognitive space.
Market Dynamics
Industry Overview
The digital therapeutics industry is growing rapidly, driven by increased awareness of mental health, technological advancements, and regulatory support for digital health solutions.
Positioning
Akili Interactive Labs aims to be a leader in prescription digital therapeutics for cognitive conditions.
Total Addressable Market (TAM)
The TAM for digital therapeutics targeting cognitive disorders is estimated to be significant and growing, but estimating a number requires detailed market research. Akili is positioned to capture a portion of this TAM through its FDA-cleared product, EndeavorRx.
Upturn SWOT Analysis
Strengths
- FDA-cleared digital therapeutic
- Focus on cognitive disorders
- Potential for high growth in digital therapeutics market
Weaknesses
- Reliance on insurance reimbursement for revenue
- Relatively new market with uncertainty in adoption
- High marketing costs to reach patients and physicians
Opportunities
- Expansion to new indications and patient populations
- Partnerships with pharmaceutical companies and healthcare providers
- Increasing acceptance of digital therapeutics by payers and patients
Threats
- Competition from other digital therapeutics and traditional treatments
- Regulatory hurdles and changing reimbursement policies
- Technological obsolescence
Competitors and Market Share
Key Competitors
- VRML
- OTLY
- OM
- TALK
- CERE
Competitive Landscape
Akili faces competition from digital therapeutics and pharmaceutical companies. Its advantage is its FDA-cleared product, but it needs to overcome reimbursement and adoption challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth will depend on Akili Interactive Labs's performance. Growth trends will need to be examined from their financial reports.
Future Projections: Future projections depend on analyst estimates for Akili Interactive Labs which are variable.
Recent Initiatives: Requires up-to-date information on Akili Interactive Labs' recent strategic moves. Partnerships, new product developments and regulatory milestones.
Summary
Denali Capital Acquisition Corp., now representing Akili Interactive Labs, is a player in the growing digital therapeutics field. Its strength lies in its FDA-cleared product, but it faces challenges in market adoption and reimbursement. Its success depends on expanding its product offerings and securing partnerships. Investors should monitor competitive pressures and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Industry Reports
- Market Analysis Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Denali Capital Acquisition Corp. Class A Ordinary Shares
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2022-06-07 | CEO & Director Mr. Lei Huang | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website |
Full time employees - | Website | ||
Denali Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with companies primarily operating in the technology, consumer services, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.